NCT04536051Unknown3 期
A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 10,300
- 试验地点
- 11
- 主要终点
- Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR
研究概览
简要总结
A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.
详细描述
There will be 2 study groups and an anticipated enrolment of 10,300 health professionals and adults with high potential for exposure to SARS-CoV-2, aged ≥18 years.
All subjects will undergo follow-up for a total of 1 year post last vaccination. Additional visits or procedures may be performed at the discretion of the investigators, e.g., further medical history and physical examination, or additional blood tests and other investigations if clinically relevant
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults from 18 to 55 years of age
- •Adults aged 56-69 years old (after review of safety data by DSMB in this age group in the UK trial)
- •Adults aged 70 and above years old (after review of safety data by DSMB in this age group in the UK trial)
- •Able and willing (in the Investigator's opinion) to fulfill all study requirements;
- •Health professionals and adults at high risk of exposure to SARS-CoV-2, as defined in section 5.2 of this protocol;
- •Serology with SARS-CoV-2 negative IgG antibodies; This inclusion criteria does not apply to participants enrolled from version 4.0 of the protocol onwards.
- •Willing to allow investigators to discuss the participant's clinical history with their GP/personal physician and access medical records relevant to the study procedures
- •Only for women of childbearing age willing to practice continuous effective birth control (see below) during the study, and a negative pregnancy test on the screening and vaccination day(s);
- •Consent to abstain from blood donation during the course of the study;
- •Provide informed consent in writing
排除标准
- •Participation in trials of prophylactic drugs for COVID-19 during the course of the study; Note: Participation in COVID-19 treatment trials is permitted in case of hospitalization due to COVID-19, after confirmation of positive PCR. The study team should be informed as soon as possible. Participants with COVID-19 not hospitalized with positive PCR results for COVID-19 may be medicated according to standard clinical practice.
- •Participation in SARS-CoV-2 serological research where participants are informed of their serological status during the course of the study;
- •Planned receipt of any vaccine (authorized or investigational), within 30 days before and after vaccination;
- •Prior receipt of an investigational vaccine or authorized with the possibility of impacting the interpretation of the study data (for example, vaccines vectorized by Adenovirus, any vaccines against coronavirus);
- •Administration of immunoglobulins and/or any blood products in the three months prior to the planned administration of the candidate vaccine;
- •Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia; severe recurrent infections and chronic use (more than 14 days) of immunosuppressive medication in the last 6 months, except for topical steroids or short-term oral steroids (cycle lasting ≤14 days);
- •History of allergic disease or reactions possibly exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY or paracetamol;
- •Any history of angioedema;
- •Any history of anaphylaxis;
- •Pregnancy, lactation or willingness/intention to become pregnant during the study;
- •Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ);
- •History of severe psychiatric illness that possibly affects your participation in the study;
- •Hemorrhagic disorder (for example, factor deficiency, coagulopathy or platelet disorder), or a previous history of significant bleeding or bruising after IM injections or venipuncture;
- •Current suspected or known dependence on alcohol or drugs;
- •Severe and/or uncontrolled cardiovascular diseases, respiratory diseases, gastrointestinal diseases, liver disease, kidney disease, endocrine disorder, and neurological disease (mild/moderate well-controlled comorbidities are allowed);
- •History of COVID-19 confirmed by laboratory;
- •Seropositive for antibodies to SARS-CoV-2 before recruitment; This exclusion criteria does not apply to participants enrolled from version 4.0 of the protocol onwards
- •Continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban);
- •Any other significant illness, disorder or finding that may significantly increase the risk for the participant, affect his/her ability to participate in the study or impair the interpretation of the study data.
- •Re-vaccination exclusion criteria (two-dose groups only)
- •Anaphylactic reaction following administration of vaccine
- •Pregnancy
结局指标
主要结局
Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR
时间窗: 12 months post final vaccination
COVID-19 virologically confirmed symptomatic cases (PCR positive).
次要结局
- Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination(7 days post vaccination)
- Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of serious adverse events(12 months post final vaccination)
- Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of episodes; intensified disease(12 months post final vaccination)
- Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: hospitalization for COVID-19 disease confirmed by PCR(12 months post final vaccination)
- Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: COVID-19 serious disease confirmed by PCR(12 months post final vaccination)
- Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: death associated with COVID-19 disease(6 months)
- Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates)(12 months post final vaccination)
- Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: antibodies against the SARS-CoV-2 spike protein (serum conversion rates)(12 months post final vaccination)
- Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus(12 months post final vaccination)
- Assess the cellular immunogenicity of ChAdOx1 nCoV-19 candidate vaccine(12 months post final vaccination)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve SubjectsSmallpoxNCT01144637Bavarian Nordic4,005
招募中
3 期
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan AfricaTuberculosisNCT04975178Biofabri, S.L7,120
已完成
3 期
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 YearsInfluenzaNCT00616928GlaxoSmithKline4,561
已完成
3 期
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisPsoriasisNCT02905331Janssen Research & Development, LLC78
已完成
3 期
A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101)NCT06585696Cutia Therapeutics（Wuxi）Co.,Ltd554